Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesExpanding Access to Triptans: Assessment of Clinical Outcome
Headache: The Journal of Head and Face Pain, 10/12/09
Cady R et al. – Providing a greater quantity of 10 mg rizatriptan orally disintegrating tablet (ODT) did not reduce the number of migraine days compared with providing 9 tablets per month for this population with episodic migraine with a frequency of 3–8 migraines per month. Regardless of quantity provided, rizatriptan was generally well tolerated.
Today in Neurology/Neurosurgery...keeping you current
Receive free subspecialty "5-minute updates" via email
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09
Stroke treatment with alteplase given 3·0—4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial
The Lancet Neurology, 11/17/09
Today in Pain Management...keeping you current
Receive free subspecialty "5-minute updates" via email
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09
Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/19/09
Article Search
Sponsor